Together, we can cross the finish line and make MDMA a medicine

Early next year, MAPS will publish the full results of our first of two Phase 3 clinical trials for MDMA-assisted therapy for PTSD. Phase 3 is the final stage before seeking FDA approval for a new prescription treatment.

If successful, this treatment could transform the lives of millions of people who live with the impacts of complex trauma.

On the June 4, 2021, MAPS Founder and Executive Director Rick Doblin, Ph.D., appeared on an episode of The Joe Rogan Experience, the most popular podcast in the world.

In the May 4, 2021, edition of The New York Times newspaper, the world-renowned publication reveals research results from the first Phase 3 clinical trial of MDMA-assisted therapy for posttraumatic stress disorder (PTSD).

Become a Psychedelic Advocate

Monthly MAPS donors sustain our work and support year-round psychedelic research, drug policy reform, public education, harm reduction, peer support, and general operations.

World-renowned visionary artist Alex Grey has honored MAPS by painting Psychedelic Healing, a uniquely psychedelic rendition of the MAPS logo! To celebrate MAPS' 35th anniversary, the Chapel of Sacred Mirrors (CoSM) is selling a limited series of 350 fine art prints signed by Alex Grey and MAPS Founder Rick Doblin, Ph.D.


MDMA-assisted therapy is the only treatment for PTSD designated by the FDA as a breakthrough therapy

Our highest priority project is funding clinical trials of 3,4-methylenedioxymethamphetamine (MDMA) as a tool to assist therapy for the treatment of posttraumatic stress disorder (PTSD).

We have also sponsored clinical trials of MDMA-assisted therapy for anxiety associated with life-threatening illness and social anxiety in autistic adults, LSD-assisted therapy for anxiety, and medical marijuana for PTSD in veterans of war. We have sponsored observational studies for ibogaine therapy for drug addiction and ayahuasca-assisted treatment for drug addiction and PTSD.

MDMA website

our education website

Our Education Programs

In addition to our clinical research programs, MAPS provides harm reduction training and services through the Zendo Project, advocates for reducing barriers to scientific research with psychedelics and marijuana, and curates educational events and webinars.

Our Values


Information is shared transparently. Communications are respectful, honest, and forthright, and our decisions are informed by compassion and research.


We mindfully persist in the face of challenges, and we build with a balanced, long-term vision.


We are always open to new possibilities: we try new things, take risks, and learn from our mistakes.


We work for ethical and equitable access for all.